findmyKOL

Amy Evangelisto, MD

Basic profile

Rheumatology

ORCIDNone on fileNPI
RegionVoorhees, NJ · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Amy Evangelisto is a Rheumatology/Immunology physician. OpenAlex indexes 17 publications with 252 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
17publications

Distinct works indexed by OpenAlex.

252citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

2301 E. Evesham Road
Bldg 800, Suite 115
Voorhees, NJ 08043

Telephone

856-424-5005

Registry record last updated 16 May 2018.

View the NPPES registry record

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    75.4%
    TNF inhibitor46.3%
    Certolizumab pegol68%Golimumab26%Infliximab6%Enbrel Sureclick0%Humira(Cf) Pen0%Simponi0%
    Part D + Part B<11 patients
    Interleukin-6 Receptor Antagonist24.9%
    Tocilizumab100%
    Part B, office-administered25 patients

    + 7 more classes in this area

  • Musculoskeletal

    11.6%
    RANK Ligand Inhibitor6.2%
    Denosumab100%
    Part B, office-administered72 patients
    Other drugs affecting bone structure and mineralization5.2%
    Romosozumab-aqqg100%
    Part B, office-administered18 patients

    + 6 more classes in this area

  • Cardiovascular

    6.3%
    Other lipid modifying agents6.3%
    Inclisiran100%
    Part B, office-administered17 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”